
Dia Medica Therapeutics Announces Q3 2025 Results and Key Business Updates
Dia Medica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate and Clinical Updates Dia Medica Therapeutics, a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction, and acute ischemic stroke (AIS), today announced its financial…












